Optimizerx Corporation · NASDAQ:OPRX
Optimizerx — Investor Presentation (December 2018)
25 slides from Optimizerx's investor presentation, Dec 17, 2018
Slide 1: Corporate Presentation December 2018
Optimize] Better Connections. Better Outcomes. Nasdaq:OPRX CORPORATE PRESENTATION December 2018
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward ‘See Looking Statements ‘This presentation has been prepared by Optimize Corporation ('we""us"“our,"7OptimzeRx’ othe “Company” ands made fr informational purposes ony and doesnot constitute an offerte sel ora solistaton ofan oe to buy securities, nr shall there b
Slide 3: Who We Are
Who We Are * OptimizeRx is a Digital Health company * Nation’s largest point-of-prescribe promotional platform for the pharmaceutical industry * Digital, point-of-care communication designed to improve prescription affordability and patient adherence: + Financial and Clinical Messaging (coupons, cop
Slide 4: Senior Management
Senior Management Will Febbo cEO 38+ years of enperence ending heath services financial businesses CoMedPanet eb auexwus IY Doug Baker cro 25+ years ono nok AR fet Mee, Miriam Paramore President 30+ years of heathcare & helt IT CHANGE e. Care Source HIMSS Terry Hamilton SVP Sales Nill Medimmune Be S
Slide 5: 2018: Inflection Point for HealthTech
Optimize! 2018: Inflection Point for HealthTech a Regulations, legislation, consumer activity, and changes in healthcare provider behavior driving opportunity for Digital Health Messaging 2004-2015 Electronic Health Record (EHR) usage climbs from 20% to 8794") + Interoperability becomes critical 200
Slide 6: Pharma Sales Rep Access to Physicians Severely Limited, Meanwhile Patient Costs Are Rising
Pharma Sales Rep Access to Physicians Severely Limited, Meanwhile Patient Costs Are Rising ~60% (o) of doctors’ offices now ban or severely limit access of pharma reps and ability to deliver samples and savings coupons Patients now increasingly look to their doctors to provide information on financi
Slide 7: Multiple Reasons Why Our Platform is the New Point-of-Care Solution for Communication
Multiple Reasons Why Our Platform is the New Point-of-Care Solution for Communication Optimizel? OOO WwW” ® 90% 77% 82% 26 Average dailyEHR U.S. physicians Of studies reported HCPs want use by HCP! now using improved outcomes Clinical & Patient EHR ona mn one reminders‘ Management tools Daily Basis*
Slide 8: We Deliver Digital Health Marketing Across Key Areas
We Deliver Digital Health Marketing Across 3 Key Areas Patient Financial Support $ + Savings programs: eCoupons and vouchers + Delivered electronically, then forward electronically to pharmacist or printed ical & Educational Messaging + Clinical messages + Competitive information + New formulation a
Slide 9: Pharma's Most Valued Offering to Doctors: Drug Savings Vouchers & Co-pay Coupons
Pharma’s Most Valued Offering to Doctors: 9 rns Drug Savings Vouchers & Co-pay Coupons 71% of physicians agreed that co-pay programs improve access to treatment!) 80% $50 ores mn : flyer ad 5m, of physicians polled ht were more likely to prescribe a drug with a co-pay card’) 10
Slide 10: How it Works: Financial Messaging/Savings Workflow
How it Works: Financial Messaging/Savings Workflow STEP 1: SEARCH STEP 2: SELECTION Se) eee = os + Healthcare provider searches for a brand drug within the EHR + After selection, OptimizeRx instantly returns eligible patient financial support to review + Alerted to potential savings for patient + Of
Slide 11: How it Works: Clinical and Educational Messaging
How it Works: Clinical and Educational Messaging Ce Optimize ‘Competitive Messaging: Designed to Raise Awareness of Alternative Therapy ‘Complementary Messages Displayed with Related Medications Self- Message: <q New Formulation ‘Announcements 2
Slide 12: Acquired CareSpeak Communications
Acquired CareSpeak Communications Interactive Health Messaging Platform + Mobile health messaging platform: direct, real- time interactive health messaging CareSpeak * Designed to: * Help patients manage their health: + Cost-saving co-pay programs + Medication reminders + Refill notices Need ba? Cal
Slide 13: Rapid & Expansive Growth of EHRs Creates Fragmented & Complex Health Tech Ecosystem
Rapid & Expansive Growth of EHRs Creates oeeeaee Fragmented & Complex Health Tech Ecosystem a Asa Result, EHR Amazing Charts a Market is = pee mencedien me Competitive 4 oe 550+ oven EHRs in the U.S." Care360 Epic “
Slide 14: OptimizeRx is the Leading Aggregator in the Fragmented EHR market
OptimizeRx is the Leading Aggregator in the Fragmented EHR market Amazing Bike D:Web Dis Eli Lilly. Bayer Merck Johnson & Jolinson Encompassing now | Optimize > >50% of ambulatory market! Novartis Sanofi “AstraZeneca <> NewCrop ©.) Pharma Brands
Slide 15: We Offer Strong Value Proposition to Pharma Clients & Industry Partners
We Offer Strong Value Proposition to Pharma Clients & Industry Partners + Huge Market Opportunity for All: 1.7 billion eRx transactions annually and growing. Hundreds of EHRs used constantly by heath care providers (HCPs)! + Proven Proprietary Technology: Delivered via nation’s largest promotional e
Slide 16: Strategic Partnership with Medicom Health
Optimize! Strategic Partnership with Medicom Health = won Access to Hospitals Nationwide * 600+ leading hospitals use Medicom Health’s best- in-class digital tools to engage millions of consumers * We can now deliver offers of medication savings to qualified patients in health care systems that use
Slide 17: Patient Connect: Going Global with Strategic Partnership
Optimi Patient Connect: Going Global with Strategic = Partnership London-based Patient Connect Delivers Real-time Messaging at Point-of-Care Across Europe Global Reach of Patient Connect’s Pharmacy Network , f Patient Connect * ~450 million patients") reached through global pharmacy network partners
Slide 18: Key Stats & Indicators
Key Stats & Indicators (Nasdaq: OPRX) Optimize! Net Revenue (ttm) $18.6M Net Income (mr) som ‘Accounts Receivable (mq) 352m cash (@9/30/2018) s13.5M Total Assets (ra) s192m Total Debt (ma) $o.om Tota Liabilties (ma) s26m Uprlsted to Nasdaq on June 22
Slide 19: Opportunity to Expand EHR & ePrescriber Reach and Add Brands; Large Total Addressable Market
Opportunity to Expand EHR & ePrescriber Reach Sea and Add Brands; Large Total Addressable Market ‘Opportunity to Expand , opportunity t ada Largely Untapped Total Network by 130+ Opportunity o Triple Opportunity o Ad Addressable Market: Hi ePrescrber Reach Soon $1 Billion Potential® 20
Slide 20: Highly Scalable Revenue Model - Example
Highly Scalable Revenue Model - Example“ OptimizeRx Revenue Growth from Client A $5.0M [enn m Messaging Solution B Solution A $2.4 M © Clinical $1.2M Messaging 1m Financial $0.3 M in Messaging 2016 2017 2018 2019 Optimizel? Digital Health Messaging 10 Clients | 100 clients Soluti Financial idasraain
Slide 21: Strong Momentum in Financial Performance
Strong Momentum in Financial Performance SMilions Annual Revenue Growth and GAAP Operating Income ($0.6) (0.6) 20 202 2013 2018 2015 2016 2017 rm 9/30/18 Revenue Operating Income
Slide 22: Consolidated Statement of Operations
Optimize! Consolidated Statement of Operations (in trusons) revenve . 3952 $ om 8 os DOT Revenue Related Pay is 20 Lars tors Tota Revenue 7827 Bat sais 303 Revenue Share pense sie ot 2208 1708 rs rot ens 330 Sine 2355 rss Moria sas tba seas tis Tota Operating Expenses 208 220 2923 2009 Income (os) t
Slide 23: Key Takeaways
Optimize! Key Takeaways + Market Opportunity: 1.7 billion eRx transactions Room for Growth annually, with point-of-care marketing spend increasing Total Percentage of Ambulatory HCPs Currently Reached with OptimizeRx EHR + Proven proprietary technology delivered over Network? industry's largest prom
Slide 24: Appendix
APPENDIX
Slide 25: Rx eCoupon Market Opportunity Financial Model
Optimizel? Rx eCoupon Market Opportunity Financial Model Market Penetr: 5% Market Share Potential Scenario opti et Penetration Scenario: Revenue $50M 3% Gross margin $27.5M SG&A $15.0M ~200 Million Rx ecoupon Market Net Income (pre-tax) $12.5M is worth As 1, low fixed ~$10M* ur highly costs generate